AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has launched a global Phase III study titled ‘A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.’ The study aims to evaluate the efficacy and safety of volrustomig combined with chemotherapy compared to pembrolizumab with chemotherapy for first-line treatment in patients with metastatic non-small cell lung cancer (mNSCLC) with PD-L1 < 50%.
The study tests two treatment regimens: volrustomig plus chemotherapy (carboplatin with either pemetrexed or paclitaxel) and pembrolizumab plus the same chemotherapy options. Volrustomig is an investigational drug, while pembrolizumab is an established treatment for mNSCLC.
This interventional study is randomized and open-label, with a parallel assignment model. Its primary purpose is treatment-focused, aiming to assess the comparative effectiveness of the two drug combinations.
The study began on October 24, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This update could influence AstraZeneca’s stock performance positively if volrustomig shows superior efficacy, potentially boosting investor confidence. The competitive landscape includes established treatments like pembrolizumab, making this study’s outcome significant for market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.